Genomic Health, Inc. (NASDAQ:GHDX) currently has an Average Broker Rating of 2.55. The ABR rank within the industry stands at 12. This number is based on the 11 sell-side firms polled by Zacks.
The ABR is provided by Zacks which simplfies analyst ratings into an integer based number. They use a one to five scale where they translate brokerage firm Buy/Sell/Hold recommendations into an average broker rating. A low number in the 1-2 range typically indicates a Buy, 3 represents a Hold and 4-5 represents a consensus Sell rating. Analysts on a consensus basis are expecting that the stock will reach $32.61 within the year.
Learning to secure profits from trading the stock market can involve a lot of diligent work and focus. The more experienced a trader becomes, they may be find it easier to follow good trading techniques. Having a plan may be one of the most important aspects for trading the equity market. Without a plan, traders may find themselves in a bind when faced with difficult real world decisions. When these decisions have a direct impact on profits and losses, traders need to be able to make sure that they make the best possible moves in order to avoid disaster.
Most recently Genomic Health, Inc. (NASDAQ:GHDX) posted quarterly earnings of $0.03 which compared to the sell-side estimates of -0.02. The stock’s 12-month trailing earnings per share stands at $-0.08. Shares have moved $-8.92 over the past month and more recently, $1.23 over the past week heading into the earnings announcement. There are 7 analyst projections that were taken into consideration from respected brokerage firms.
Research analysts are predicting that Genomic Health, Inc. (NASDAQ:GHDX) will report earnings of $0.09 per share when the firm issues their next quarterly report. This is the consensus earnings per share number according to data from Zack’s Research.
Genomic Health, Inc. (NASDAQ:GHDX) closed the last session at $29.52 and sees an average of 109121.25 shares trade hands in each session. The 52-week low of the stock stands at $26.71 while the current level stands at 39.3% of the 52-week High-Low range. Looking further out we can see that the stock has moved -8.18% over the past 12 weeks and 0.44% year to date.
3 analysts rate Genomic Health, Inc. a Buy or Strong Buy, which is 27.27% of all the analyst ratings.
This article is informational purposes only and should not be considered a recommendation to buy or sell the stock.